JP2013523694A - 局所麻酔薬の生体接着性組成物 - Google Patents
局所麻酔薬の生体接着性組成物 Download PDFInfo
- Publication number
- JP2013523694A JP2013523694A JP2013501854A JP2013501854A JP2013523694A JP 2013523694 A JP2013523694 A JP 2013523694A JP 2013501854 A JP2013501854 A JP 2013501854A JP 2013501854 A JP2013501854 A JP 2013501854A JP 2013523694 A JP2013523694 A JP 2013523694A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- composition according
- amount
- local anesthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 155
- 239000003589 local anesthetic agent Substances 0.000 title claims abstract description 76
- 239000000227 bioadhesive Substances 0.000 title claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 60
- 229960005015 local anesthetics Drugs 0.000 claims abstract description 23
- 238000011200 topical administration Methods 0.000 claims abstract description 7
- 239000012074 organic phase Substances 0.000 claims abstract description 6
- 230000008961 swelling Effects 0.000 claims abstract description 5
- 229960001549 ropivacaine Drugs 0.000 claims description 66
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 28
- 239000000194 fatty acid Substances 0.000 claims description 28
- 229930195729 fatty acid Natural products 0.000 claims description 28
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 25
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 25
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 25
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 25
- 239000005642 Oleic acid Substances 0.000 claims description 25
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 25
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 25
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 25
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 25
- 150000004665 fatty acids Chemical class 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 14
- 230000003444 anaesthetic effect Effects 0.000 claims description 14
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 13
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims description 12
- 229960003656 ricinoleic acid Drugs 0.000 claims description 12
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims description 12
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 10
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 10
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 9
- 229920000136 polysorbate Polymers 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 229940074076 glycerol formal Drugs 0.000 claims description 8
- 229960004194 lidocaine Drugs 0.000 claims description 8
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 8
- 229950008882 polysorbate Drugs 0.000 claims description 8
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002372 tetracaine Drugs 0.000 claims description 7
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 7
- 235000021314 Palmitic acid Nutrition 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 6
- 229960001807 prilocaine Drugs 0.000 claims description 6
- -1 sorbitan fatty acid esters Chemical class 0.000 claims description 6
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 229960005274 benzocaine Drugs 0.000 claims description 5
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 5
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003150 bupivacaine Drugs 0.000 claims description 4
- 235000021588 free fatty acids Nutrition 0.000 claims description 4
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims description 4
- 229960004288 levobupivacaine Drugs 0.000 claims description 4
- 229960002409 mepivacaine Drugs 0.000 claims description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 229960002023 chloroprocaine Drugs 0.000 claims description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 1
- 229940068965 polysorbates Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 62
- 239000000499 gel Substances 0.000 description 39
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 35
- 229920000053 polysorbate 80 Polymers 0.000 description 35
- 239000012071 phase Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000446313 Lamella Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 5
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002535 lyotropic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- AFSHUZFNMVJNKX-UHFFFAOYSA-N 1,2-di-(9Z-octadecenoyl)glycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCC=CCCCCCCCC AFSHUZFNMVJNKX-UHFFFAOYSA-N 0.000 description 2
- LWNPNOFGINFGGV-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;2-(dimethylamino)ethyl 4-(butylamino)benzoate Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 LWNPNOFGINFGGV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004976 Lyotropic liquid crystal Substances 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000374 eutectic mixture Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- FABAOYOFJNAVHB-KVVVOXFISA-N (z)-octadec-9-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FABAOYOFJNAVHB-KVVVOXFISA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940052264 other local anesthetics in atc Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000004215 spore Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1050322 | 2010-04-01 | ||
| SE1050322-5 | 2010-04-01 | ||
| US32542510P | 2010-04-19 | 2010-04-19 | |
| US61/325,425 | 2010-04-19 | ||
| PCT/EP2011/055025 WO2011121082A1 (en) | 2010-04-01 | 2011-03-31 | Bioadhesive compositions of local anaesthetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523694A true JP2013523694A (ja) | 2013-06-17 |
| JP2013523694A5 JP2013523694A5 (enExample) | 2014-05-22 |
Family
ID=44278867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501854A Pending JP2013523694A (ja) | 2010-04-01 | 2011-03-31 | 局所麻酔薬の生体接着性組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20130079371A1 (enExample) |
| EP (1) | EP2552409A1 (enExample) |
| JP (1) | JP2013523694A (enExample) |
| KR (1) | KR20130080435A (enExample) |
| CN (1) | CN102869344A (enExample) |
| AU (1) | AU2011234415C1 (enExample) |
| BR (1) | BR112012024885A2 (enExample) |
| CA (1) | CA2794280A1 (enExample) |
| CL (1) | CL2012002705A1 (enExample) |
| EA (1) | EA201290790A1 (enExample) |
| IL (1) | IL222225A0 (enExample) |
| MX (1) | MX2012011261A (enExample) |
| NZ (1) | NZ602540A (enExample) |
| PH (1) | PH12012501887A1 (enExample) |
| SG (1) | SG184072A1 (enExample) |
| WO (1) | WO2011121082A1 (enExample) |
| ZA (1) | ZA201206989B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017082121A1 (ja) | 2015-11-12 | 2017-05-18 | テルモ株式会社 | 徐放性局所投与剤 |
| US10517859B2 (en) | 2015-03-25 | 2019-12-31 | Terumo Kabushiki Kaisha | Gel local anesthetic agent and gel local anesthetic preparation using same |
| JP2020519635A (ja) * | 2017-05-08 | 2020-07-02 | アリヴィオ セラピューティクス, インコーポレイテッド | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9642912B2 (en) | 2006-03-06 | 2017-05-09 | Crescita Therapeutics Inc. | Topical formulations for treating skin conditions |
| US9308181B2 (en) | 2006-03-06 | 2016-04-12 | Nuvo Research Inc. | Topical formulations, systems and methods |
| US20110229565A1 (en) | 2008-09-17 | 2011-09-22 | Karp Jeffrey M | Drug Delivery Composition Comprising a Self-Assembled Gelator |
| JP2013540757A (ja) | 2010-09-24 | 2013-11-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル |
| US10220093B2 (en) | 2013-02-28 | 2019-03-05 | Mira Pharma Corporation | Long-acting semi-solid lipid formulations |
| EP2961380B1 (en) * | 2013-02-28 | 2020-04-08 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid formulations and its compositions |
| GB201317718D0 (en) | 2013-10-07 | 2013-11-20 | Buzzz Pharmaceuticals Ltd | Novel formulation |
| WO2018144991A1 (en) | 2017-02-03 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| US10561606B2 (en) | 2017-12-06 | 2020-02-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid gel formulations |
| US11426418B2 (en) | 2017-12-06 | 2022-08-30 | Mira Pharma Corporation | Injectable long-acting semi-solid gel formulations |
| JP7046396B2 (ja) | 2017-12-06 | 2022-04-04 | 湖州惠中濟世生物科技有限公司 | 注射可能な長時間作用性局所麻酔薬半固形製剤 |
| US11839605B2 (en) | 2018-10-11 | 2023-12-12 | Alivio Therapeutics, Inc. | Non-injectable hydrogel formulations for smart release |
| EP4284272A4 (en) * | 2021-01-29 | 2024-12-25 | Insitu Biologics, Inc. | COMPOSITIONS AND METHODS OF SUSTAINED TREATMENT OF PAIN |
| CN118697692B (zh) * | 2024-06-27 | 2024-11-26 | 山东中医药大学附属医院 | 一种防苦麻醉胶浆剂、方法及应用 |
| CN119587525B (zh) * | 2024-11-07 | 2025-09-05 | 海南三帝制药有限公司 | 一种二甲卡因复合制剂及其制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01156919A (ja) * | 1987-06-24 | 1989-06-20 | Fujisawa Pharmaceut Co Ltd | 経皮吸収用製剤 |
| JPH09510980A (ja) * | 1994-03-30 | 1997-11-04 | デュメックス―アルファルマ エイ/エス | 生物付着性物質としての脂肪酸エステルの使用 |
| JP2008100939A (ja) * | 2006-10-18 | 2008-05-01 | Nichiban Co Ltd | 皮膚刺激の少ない経皮吸収型製剤 |
| JP2008526934A (ja) * | 2005-01-14 | 2008-07-24 | カムルス エービー | GnRH類似体製剤 |
| JP2009518374A (ja) * | 2005-12-07 | 2009-05-07 | ファーマコデックス リミテッド | 活性薬剤、特にジクロフェナクの経皮投与 |
| JP2009537513A (ja) * | 2006-05-16 | 2009-10-29 | マクニール アーベー | トロメタモールを緩衝性作用物質として含有する、ニコチンの口腔内送り込み用薬用製品 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601421D0 (sv) | 1996-04-12 | 1996-04-12 | Astra Ab | New composition |
| ATE214599T1 (de) * | 1996-10-14 | 2002-04-15 | Kowa Co | Lokalanästhetikum zur aüsserlichen anwendung |
| US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| WO2004071398A2 (en) * | 2003-02-17 | 2004-08-26 | Cipla Ltd | Pharmaceutical patch |
| US20050084508A1 (en) | 2003-07-22 | 2005-04-21 | Vancaillie Thierry G. | Topical anesthesia formulation for bodily cavities |
| JP4931369B2 (ja) | 2005-05-31 | 2012-05-16 | ポーラ化成工業株式会社 | リポソームおよびそれを含む処置用の組成物 |
| CA2623561C (en) * | 2005-09-27 | 2015-04-28 | Efrat Biopolymers Ltd. | Gelling hydrophobic injectable polymer compositions |
| US20070280972A1 (en) * | 2006-04-25 | 2007-12-06 | Zars, Inc. | Adhesive solid gel-forming formulations for dermal drug delivery |
| US9918934B2 (en) | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
| US20090247494A1 (en) | 2008-04-01 | 2009-10-01 | Phillip Mark Kofsky | Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders |
-
2011
- 2011-03-31 SG SG2012068250A patent/SG184072A1/en unknown
- 2011-03-31 CA CA2794280A patent/CA2794280A1/en not_active Abandoned
- 2011-03-31 PH PH1/2012/501887A patent/PH12012501887A1/en unknown
- 2011-03-31 JP JP2013501854A patent/JP2013523694A/ja active Pending
- 2011-03-31 CN CN2011800166567A patent/CN102869344A/zh active Pending
- 2011-03-31 BR BR112012024885A patent/BR112012024885A2/pt not_active IP Right Cessation
- 2011-03-31 NZ NZ602540A patent/NZ602540A/en not_active IP Right Cessation
- 2011-03-31 EP EP11711566A patent/EP2552409A1/en not_active Withdrawn
- 2011-03-31 KR KR1020127028642A patent/KR20130080435A/ko not_active Withdrawn
- 2011-03-31 EA EA201290790A patent/EA201290790A1/ru unknown
- 2011-03-31 US US13/638,519 patent/US20130079371A1/en not_active Abandoned
- 2011-03-31 MX MX2012011261A patent/MX2012011261A/es not_active Application Discontinuation
- 2011-03-31 AU AU2011234415A patent/AU2011234415C1/en not_active Ceased
- 2011-03-31 WO PCT/EP2011/055025 patent/WO2011121082A1/en not_active Ceased
-
2012
- 2012-09-18 ZA ZA2012/06989A patent/ZA201206989B/en unknown
- 2012-09-27 IL IL222225A patent/IL222225A0/en unknown
- 2012-09-27 CL CL2012002705A patent/CL2012002705A1/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01156919A (ja) * | 1987-06-24 | 1989-06-20 | Fujisawa Pharmaceut Co Ltd | 経皮吸収用製剤 |
| JPH09510980A (ja) * | 1994-03-30 | 1997-11-04 | デュメックス―アルファルマ エイ/エス | 生物付着性物質としての脂肪酸エステルの使用 |
| JP2008526934A (ja) * | 2005-01-14 | 2008-07-24 | カムルス エービー | GnRH類似体製剤 |
| JP2009518374A (ja) * | 2005-12-07 | 2009-05-07 | ファーマコデックス リミテッド | 活性薬剤、特にジクロフェナクの経皮投与 |
| JP2009537513A (ja) * | 2006-05-16 | 2009-10-29 | マクニール アーベー | トロメタモールを緩衝性作用物質として含有する、ニコチンの口腔内送り込み用薬用製品 |
| JP2008100939A (ja) * | 2006-10-18 | 2008-05-01 | Nichiban Co Ltd | 皮膚刺激の少ない経皮吸収型製剤 |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10517859B2 (en) | 2015-03-25 | 2019-12-31 | Terumo Kabushiki Kaisha | Gel local anesthetic agent and gel local anesthetic preparation using same |
| WO2017082121A1 (ja) | 2015-11-12 | 2017-05-18 | テルモ株式会社 | 徐放性局所投与剤 |
| JP2020519635A (ja) * | 2017-05-08 | 2020-07-02 | アリヴィオ セラピューティクス, インコーポレイテッド | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2022103299A (ja) * | 2017-05-08 | 2022-07-07 | アリヴィオ セラピューティクス, インコーポレイテッド | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP7211974B2 (ja) | 2017-05-08 | 2023-01-24 | アリヴィオ セラピューティクス, インコーポレイテッド | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023041861A (ja) * | 2017-05-08 | 2023-03-24 | アリヴィオ セラピューティクス, インコーポレイテッド | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20130079371A1 (en) | 2013-03-28 |
| SG184072A1 (en) | 2012-10-30 |
| AU2011234415A1 (en) | 2012-10-18 |
| CA2794280A1 (en) | 2011-10-06 |
| MX2012011261A (es) | 2012-12-05 |
| WO2011121082A1 (en) | 2011-10-06 |
| EP2552409A1 (en) | 2013-02-06 |
| EA201290790A1 (ru) | 2013-04-30 |
| AU2011234415B2 (en) | 2014-04-10 |
| CN102869344A (zh) | 2013-01-09 |
| CL2012002705A1 (es) | 2013-02-01 |
| AU2011234415C1 (en) | 2014-07-10 |
| NZ602540A (en) | 2014-05-30 |
| PH12012501887A1 (en) | 2012-12-17 |
| BR112012024885A2 (pt) | 2016-06-21 |
| KR20130080435A (ko) | 2013-07-12 |
| IL222225A0 (en) | 2012-12-31 |
| ZA201206989B (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523694A (ja) | 局所麻酔薬の生体接着性組成物 | |
| JP5972862B2 (ja) | 熱ゲル化麻酔組成物 | |
| CN102892408A (zh) | 适于局部麻醉剂的无水药物组合物 | |
| AU2019203449A1 (en) | Topical diclofenac sodium compositions | |
| JP5642658B2 (ja) | 非水性貼付剤 | |
| JP4500013B2 (ja) | 局所麻酔組成物 | |
| JP2023092097A (ja) | 非水系貼付剤およびその製造方法 | |
| JP2021080170A (ja) | 非水系貼付剤 | |
| JPH0477425A (ja) | インドメタシン含有貼付剤 | |
| JP2024519493A (ja) | 局所ナプロキセン製剤及びそれらの使用 | |
| CN114302707A (zh) | 局部阿昔洛韦制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140331 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140331 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141118 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150218 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150721 |